Clinical Trials Browser

Phase 3 × Completed × regorafenib × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05600309 2025-11-26

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Phase 3 Completed

94 enrolled 15 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05064059 2025-09-17

MK-4280A-007

Phase 3 Completed

441 enrolled 24 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT02934529 2025-04-16

AIO-KRK-0114

Phase 3 Completed

673 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03465722 2022-10-06

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

Phase 3 Completed

476 enrolled 14 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01271712 2021-01-29

GRID

Phase 3 Completed

199 enrolled 17 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01774344 2020-08-20

RESORCE

Phase 3 Completed

573 enrolled 23 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT02788279 2019-12-11

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

Phase 3 Completed

363 enrolled 19 charts

Gastrointestinal

Colorectal Neoplasms

NCT01853319 2019-04-22

REGARD

Phase 3 Completed

100 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT01584830 2016-02-08

CONCUR

Phase 3 Completed

204 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT01103323 2015-06-24

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Phase 3 Completed

760 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

MK-7902-017

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

MK-4280A-007

AIO-KRK-0114

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

GRID

RESORCE

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

REGARD

CONCUR

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy